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Abstract Finding the optimal pharmacological treatment of a
patent ductus arteriosus (PDA) in preterm neonates remains
challenging. There is a growing interest in paracetamol as a
new drug for PDA closure. In this prospective observational
cohort study, we evaluated the effectiveness of intravenous
paracetamol in closing a PDA in very low birth weight infants
with a hemodynamically significant PDA who either did not
respond to ibuprofen or had a contraindication for ibuprofen.
They received high-dose paracetamol therapy (15 mg/kg/6 h
intravenous) for 3–7 days. Cardiac ultrasounds were performed
before and 3 and 7 days after treatment. Thirty-three patients
were included with a median gestational age of 251/7 weeks
(IQR 1.66), a median birth weight of 750 g (IQR 327), and a
median postnatal age of 14 days (IQR 12). Paracetamol was
ineffective in 27/33 patients (82 %). Even more, after previous
exposure to ibuprofen, this was even 100 %.
Conclusion: In this study, paracetamol after ibuprofen
treatment failure was not effective for PDA closure in VLBW
infants. From the findings of this study, paracetamol treatment
for PDA closure cannot be recommended for infants with a
postnatal age >2weeks. Earlier treatment with paracetamol for
PDA might be more effective.
What is known:
• The ductus arteriosus fails to close after birth in 30 to 60% of
prematurely born neonates and is a significant cause of morbidity and
mortality in these infants.
• Paracetamol gained importance as an alternative drug in PDA closure.
What is new:
• Paracetamol for PDA closure after ibuprofen treatment failure was not
effective in VLBW infants.
• Effect of paracetamol on PDA closure was observed when given as
primary treatment.
Communicated by Patrick Van Reempts
Dick Tibboel
d.tibboel@erasmusmc.nl
Sinno H. P. Simons
s.simons@erasmusmc.nl
1 Department of Pediatrics, Division of Neonatology, Erasmus
MC—Sophia Children’s Hospital, Room Sp2463, Wytemaweg 80,
3015 CN Rotterdam, The Netherlands
2 Department of Pediatric Cardiology, Erasmus MC—Sophia
Children’s Hospital, Rotterdam, The Netherlands
3 Intensive Care and Department of Pediatric Surgery, Erasmus
MC—Sophia Children’s Hospital, Rotterdam, The Netherlands
4 Department of Pediatric Pharmacology, University Children’s
Hospital, Basel, Switzerland
Eur J Pediatr (2015) 174:1433–1440
DOI 10.1007/s00431-015-2541-5
* Daniëlla W. E. Roofthooft
d.roofthooft@erasmusmc.nl
Ingrid M. van Beynum
i.vanbeynum@erasmusmc.nl
Johan C. A. de Klerk
j.deklerk@erasmusmc.nl
Monique van Dijk
m.vandijk.3@erasmusmc.nl
John N. van den Anker
jvandena@cnmc.org
Irwin K. M. Reiss
i.reiss@erasmusmc.nl
Keywords Paracetamol . Patent ductus arteriosus . VLBW
infants . Ibuprofen contraindication . Ibuprofen treatment
failure
Abbreviations
hsPDA Hemodynamically significant patent
ductus arteriosus
IQR Interquartile range
LA/Ao ratio Left atrial to aortic root ratio
LPA Left pulmonary artery
NEC Necrotizing enterocolitis
NSAIDs Non-steroidal anti-inflammatory drugs
PDA Patent ductus arteriosus
VLBW Very low birth weight
Introduction
The ductus arteriosus fails to close after birth in 30 to 60 % of
prematurely born infants [16]. This condition—patent ductus
arteriosus (PDA)—is associated with a prolonged ventilation
need and carries an increased risk of morbidity (i.e., necrotizing
enterocolitis, chronic lung disease) and even mortality [10, 15,
18]. Pharmacological closure with non-steroidal anti-inflamma-
tory drugs (NSAIDs), mainly ibuprofen and indomethacin, is
currently the standard of care [27]. NSAIDs are not effective
in around 30 % of patients, however, and can have side effects
such as gastrointestinal bleeding and perforation, diminished
platelet aggregation, hyperbilirubinemia, and transient renal
function impairment [22, 23]. Moreover, NSAIDs are contrain-
dicated in a considerable proportion of newborns, notably those
with renal failure, intracerebral hemorrhage, gastrointestinal
problems, and thrombocytopenia. If NSAIDs fail or are contra-
indicated, the only currently available solution is surgical liga-
tion, which is associated with the risks of cardiothoracic surgery
and impaired neurological outcome [17]. Therefore, alternative
pharmacological interventions are needed.
Paracetamol has been suggested as an alternative drug for
PDA closure [21]. More than 10 observational and retrospec-
tive studies have described oral or intravenous high-dose para-
cetamol treatment with varying effectiveness [1, 8, 9, 11, 12,
19, 21, 26, 29] (see Table 1). Two recent prospective random-
ized controlled trials comparing oral paracetamol with ibupro-
fen both showed a slightly favorable effect of paracetamol
(closure rate 81.2 versus 78.8 % for ibuprofen) [5]. The other
trial by Oncel et al. even showed a higher closure success rate
in the paracetamol group (97.5 versus 95 % in the ibuprofen
group) after a maximum of two courses of ibuprofen or
paracetamol [20].
After publication of the first studies on paracetamol and
PDA closure, we added intravenous paracetamol to our PDA
treatment guideline. However, the results in the first patients
did not match the high closure rates of other studies, and only
20 % of patients did not need further PDA treatment after
paracetamol [24]. Based on the promising results of other
published studies, we decided to continue paracetamol treat-
ment for PDA closure in preterm infants with ibuprofen con-
traindications or ibuprofen treatment failure.
In the current study, we describe the evaluation of the effi-
cacy of intravenous paracetamol on PDA closure in very low
birth weight (VLBW) infants admitted to our hospital.
Methods
In a prospective observational, single center study performed
from December 2012 until September 2014, at the level III
NICU of the Erasmus MC—Sophia Children’s Hospital in
Rotterdam, the Netherlands, we included all neonates with a
gestational age of less than 28 weeks and a birth weight of less
than 1500 g, diagnosed with a hemodynamically significant
patent ductus arteriosus (hsPDA) using clinical and cardiac
ultrasound evaluation. Findings in the first nine patients in
the current study were also presented in a preliminary report
in 2014 [4].
The first drug of choice in our department for PDA treatment
was intravenous ibuprofen (Neobrufen©; Pedea ©), a single
daily dose for 3 days (10 mg/kg on the first day, 5 mg/kg on
the second and third days), and a repeated 3-day course if clo-
sure was not yet obtained. Paracetamol (Perfalgan©; Bristol-
Meyers Squibb) was given if two courses of ibuprofen had no
effect or if ibuprofen was contraindicated. Intravenous paracet-
amol 15 mg/kg every 6 h (60 mg/kg/day) was administered for
a minimum of 3 days and a maximum of 7 days.
Based on the indication for paracetamol, we created three
groups. Group A: ibuprofen contraindicated and paracetamol
as first drug of choice (primary contraindication); group B:
development of a contraindication for ibuprofen during treat-
ment with ibuprofen as first choice and switch to paracetamol
(incomplete ibuprofen); and group C: two complete courses of
ibuprofen failed to achieve closure and switch to paracetamol
(complete ibuprofen) (see Fig. 1).
Contraindications for ibuprofen treatment were active
intracerebral hemorrhage, thrombocytopenia or other
known clotting disorders, severe sepsis, suspected or con-
firmed necrotizing enterocolitis (NEC), intestinal perfora-
tion, liver and kidney function disorders (oliguria
<1.0 ml/kg/h, serum creatinine >110 μmol/l) and severe
hyperbilirubinemia.
Echocardiographic examination was performed by the
echocardiosonographer or pediatric cardiologist before the
start of paracetamol treatment, after 3 days and after
7 days. Measurements included ductus diameter, PDA
diameter/LPA (left pulmonary artery) diameter, and LA/
Ao (left atrial to aortic root) ratio. Two-dimensional color
Doppler echocardiography was performed using a Vivid-
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S6 (GE Health Care) ultrasound system equipped with a
10-MHz transducer.
Cardiac ultrasound studies were done at the bedside by
different echocardiosonographers, and measurements were
checked by one pediatric cardiologist (I. M. v B.). HsPDA
closure was defined as no flow through the duct. An open
duct with diameter <1.5 mm, without significant left-to-
right shunt, PDA:LPA diameter <0.5 and LA/Ao ratio
<1.4 was defined as small PDA and not hemodynamically
significant. HsPDA was defined as a ductal diameter of
>2.0 mm, PDA:LPA diameter >0.8 and/or LA/Ao ratio
>1.6.
Statistical analysis
Patient characteristics are presented as medians (IQR: inter-
quartile range) in case of non-normally distributed variables
and as means (standard deviations) in case of normally dis-
tributed variables. PDA diameters, PDA:LPA ratio and LA/
Ao ratio before, during, and after treatment with paracetamol
were compared using paired t tests. Fisher exact tests were
used in case of categorical variables. Data analyses were per-
formed with SPSS version 21.0 (SPSS Inc.). A p value of 0.05
was set as statistically significant.
Results
A total of 33 VLBW infants with a median gestational age of
251/7 weeks (range 236/7–266/7, IQR 1.66) and a median birth
weight of 750 g (range 365–1130, IQR 327) were included.
Intravenous paracetamol was started at a median postnatal age
of 14 days (IQR 12). Background characteristics and clinical
outcome are shown in Table 2.
Median duration of paracetamol treatment was 6 days (IQR
3); the median cumulative dose was 360 mg (IQR 180). Duc-
tal closure or no hsPDA after treatment was achieved in six of
the 33 patients (18 %). In total, 23 patients (76.7 %) needed
surgical ligation for hsPDAwith clinical symptoms. Findings
in the three different groups (see Fig. 1) are detailed below.
Patients in group A (=primary contraindication for ibupro-
fen;N=13, 39.4%) received the first dose of paracetamol after
a median of 12 (IQR 11.5) postnatal days and the median
duration of the course was 6 (IQR 3) days. In six patients
(46 %), the ductus arteriosus was closed or not hemodynam-
ically significant after paracetamol and further treatment was
not indicated. Two of the seven patients who did not respond
to paracetamol treatment were successfully treated with ibu-
profen (one and two courses, respectively) afterwards because
the contraindication for ibuprofen had disappeared. Surgical
ligation was performed in the other five (54 %).
Table 1 Literature review on PDA treatment with paracetamol
Author Dose
(mg/kg/day)
Treatment
interval (h)
Route Treatment
PCM (days)
Gestational
age (weeks)
PN age start
PCM (days)
Patients that achieved ductal
closure/no surgical ligation
1. Hammerman 2011 15 6 Oral Max. 7 26–296/7 3–35 5/5
2. Yurttutan 2013 15 6 Oral Max. 6 26–30 3–7 5/6
3. Oncel 2013 15 6 Intravenous 3–6 24–29 2–15 10/10
4. Alan 2013 15 6 Intravenous Max. 19 262/7–335/7 8–19 0/3
5. Özmert 2013 15 6 Oral 3–6 23–32 20–47 5/7
6. Sinha 2013 15 8 Oral 2 27–33 4–7 10/10
7. Kessel 2013 15 6 Oral 3–11 26–30 ? 7/7
8. Jasani 2013 15 6 Oral 2.3–4.3 28.5–31.1 2.6–8.9
9. Dang 2013 RCT 15 6 Oral 3 31.2±1.8 65/80
10. Oncel 2013 RCT 15 6 Oral 3–6 ≤26 2–3 12/13
15 6 Oral 3–6 <28 2–3 22/23
11. Tekgunduz 2014 15 6 Intravenous 1 29 3 0/1a
10 8 Intravenous 1–4 24–31 2–9 10/12b
12. Nadir 2014 15 6 Oral Max. 7 24–27 2–22 4/7
13. el-Khuffash 2014 15 6 Oral 2 26–33 14–56 0/5
15 6 Oral 7 26–30 8–35 6/7
15 6 Intravenous 2–5 26–32 3–41 9/9
14. Terrin 2014 7.5–15 max. 60 4–6 Intravenous 3 26±2 2.8±1.2 6/8
15. Roofthooft 2014 15 6 Intravenous 3–7.5 236/7–264/7 3–33 6/33
16. el-Khuffash 2015 15 6 Intravenous Max. 6 24.6–27.9 16–39 24/30
a Transaminases elevated: paracetamol treatment stopped after three doses, ductal closure with oral ibuprofen
bDuctal closure of two remaining PDAs with oral ibuprofen after paracetamol
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Patients in group B (=incomplete ibuprofen; N=8,
24.2 %) received the first dose of paracetamol after a median
of 12.5 (IQR 14.75) postnatal days and the median duration
of the course was 6.5 (IQR 2.75) days. Two patients died on
the 24th and 34th postnatal day (i.e., sepsis with extension
of bilateral intraventricular hemorrhage with venous infarc-
tion, gram-negative bacterial infection) after paracetamol
treatment (started on day 8 and 13, respectively) before a
decision could be made to treat the persistent PDA with
surgical closure.
Paracetamol treatment was ineffective in the six remaining
patients and all underwent surgical closure of the duct.
Patients in group C (=complete ibuprofen; N=12, 36.4 %)
received paracetamol for a median of 5.5 days (IQR 4) after
two courses of ibuprofen. At the start of paracetamol treat-
ment, their median postnatal age was 16.5 (IQR 10.75) days.
Paracetamol treatment was ineffective in all patients, and con-
sequently, they all underwent surgical ligation.
Both the surgical ligation rate and the mortality rate dif-
fered between the three groups. Surgical ligation was per-
formed in 5/13 (38.5 %) patrients in group A; 6/8 (75 %) in
group B; and 12/12 (100 %) in group C (Fisher exact test for
surgical ligation p=0.001). In total, eight patients died (Fisher
exact test for death p=0.025): 4/13 (31%) in group A (median
51 days; IQR 24.5); 4/8 (50 %) in group B (median 30 days;
IQR 34.3); and none in group C. Two of the four non-
survivors in group B died from the consequences of NEC
before surgical closure of the PDA could be performed.
Cardiac ultrasound studies showed a statistically signifi-
cant decrease in ductal diameter after paracetamol treatment
only in group A, from median 2.4 to 1.8 mm after 7 days of
treatment (p=0.035, paired t test) (Fig. 2).
All pre- and posttreatment measurements of kidney func-
tion (urea and creatinine) and liver function (transaminases,
conjugated bilirubin) were normal.
Discussion
In this study, high-dose intravenous paracetamol for the treat-
ment of hsPDA in VLBW infants was overall effective in only
18%. Looking at the subgroups of patients, paracetamol treat-
ment was completely ineffective after previous ibuprofen
treatment failure. However, it was effective in 46 % of the
newborns with primary contraindications for ibuprofen.
Group A
Group B
Group C
N=33
paents with
PDA
N=13
contraindicaon
for ibuprofen
PCM
N=12
complete
ibuprofen
N=8
Incomplete
ibuprofen
N=6 ductus closed/
hemodyn not sign.
N=7 ductus open
N=12 surgical
closure
N=6 surgical
closure; N=2
died
N=5 surgical
closure
N=2 ductus closed
aer 3-6 doses
inbuprofen
N=12
Ductus
PCM
N=20 treated
with ibuprofen
PCM
N=3 NEC; N=1 caecum
perforaon; N=1 IVH+venous
infarcon; N=1 sepsis; N=1
feeding intolerance; N=1 lung
hemorrhage
N=8
Ductus
N=12
Ductus
N=1 IVH; N=2 intesnal
perforaon; N=4 NEC; N=1
trombocytopenia; N=1 Meckel’s
diverculum; N=1 feeding
intolerance; N=3 combinaon of
contraindicaons
Fig. 1 Flowchart included patients
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The variability in success rates of this paracetamol thera-
py for PDA closure is hard to explain. Other studies reported
success rates of 0 [7] up to 100 % [12, 19]. Success rates in
two RCTs comparing oral paracetamol versus oral ibuprofen
were 81 [5] and 94 % [20], respectively, thus, much higher
than in our study. Still, in all but one of those studies, the
same dosing regimen of 60 mg/kg/24 h paracetamol was
used. In the study by Tekgunduz et al. the dose was lowered
to 30 mg/kg/day after a patient showed elevated
transaminases [13]. The duration of paracetamol treatment
in our study was 6.0 days compared to 4.1 days [29] and
3.9 days [19] in the studies with high success rates.
In previous studies, except in the two RCTs [5, 20],
the indication for paracetamol was the same as in our
study (treatment failure or contraindication for ibupro-
fen). The interpretation of different studies on this sub-
ject seems to be hindered by the lack of an international
guideline on the definition of hsPDA and cutoff values
Table 2 Background characteristics
Characteristics Group A
N=13
Group B
N=8
Group C
N=12
Gestational age (weeks); median 25.2 24.3 25.8
Range 24.0–26.4 24.0–26.3 23.6–26.6
IQR 0.8 0.7 1.0
Birth weight (g): median 650 730 868
Range 400–1130 365–820 480–990
IQR 360.0 305.0 231.3
Small for gestational age: n (%) 5 (38.5) 3 (37.5) 2 (16.7)
Gender
Male: n (%) 9 (69.2) 4 (50) 6 (50)
Female: n (%) 4 (30.8) 4 (50) 6 (50)
Died: n (%) 4 (30.8) 4 (50) 0 (0)
Post natal age: median/IQR 51/24.5 30/34.3
Antenatal steroids: n (%) 11 (84.6) 8 (100) 12 (100)
PIH: n (%) 3 (23.1) 2 (25) 2 (16.7)
Cesarean section: n (%) 9 (69.2) 5 (62.5) 7 (58.3)
Mechanical ventilation: n (%) 12 (92.3) 7 (87.5) 11 (91.7)
Surfactant treatment 10 (76.9) 7 (87.5) 11 (91.7)
Diuretics 11 (84.6) 4 (50) 11 (91.7)
Fluid restriction 9 (69.2) 3 (37.5) 8 (66.7)
PNA start PCM: median (days) 12.0 12.5 16.5
IQR 11.5 14.75 10.75
Paracetamol treatment 6.0 6.5 5.5
Days in total (median/IQR) 3 2.75 4
Surgical ligation: n (%) 5 (38.5) 6 (75.0) 12 (100)
PDA diameter before start PCM (mm): median/IQR 2.4/1.30 1.9/1.13 .4/0.83
PDA diameter after 3 days PCM (mm): median/IQR 1.9/0.90 2.1/1.13 2.1/1.08
PDA diameter after 7 days PCM (mm): median/IQR 1.8/1.28 2.0/0.40 2.6/1.60
PDA:LPA ratio before start PCM median/IQR 0.85/0.55 0.85/0.45 0.90/0.30
PDA:LPA ratio after 3 days PCM median/IQR 0.90/0.60 0.80/0.15 0.95/0.50
PDA:LPA ratio after 7 days PCM median/IQR 0.75/0.58 0.80/0.30 0.85/0.28
LA/Ao ratio before start PCM median/IQR 1.6/0.30 1.7/0.53 1.75/0.30
LA/Ao ratio after 3 days PCM median/IQR 1.64/0.60 1.7/0.70 1.8/0.55
LA/Ao ratio after 7 days PCM median/IQR 1.4/0.55 1.9/0.40 1.7/0.65
NT-proBNP (pmol/l)a: median 1097 2102 3078
IQR 3849.3 5832.0 4981.8
PIH pregnancy induced hypertension syndrome, PNA postnatal age, PCM paracetamol, LPA left pulmonary artery, LA-Ao left atrium-Aorta,NT-proBNP
N-terminal pro-brain natriuretic peptide
a All NT-proBNP values were determined on day 3 PNA
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for a small, medium, or large PDA (cardiac ultrasound
measurements).
It is remarkable that Oncel et al. reported a 100 % success
rate of PDA closure with intravenous paracetamol [19], the
same administration route as in our study. Although unlikely,
the route of administration could in part explain the variety in
success rates; as long as data on bioavailability of the drug in
the different routes and enterohepatic recirculation are lacking,
we cannot tell which route of administration is superior. Still,
ibuprofen studies also tend to find better results with oral
administration [27]. Intravenous therapy probably leads to
high peak plasma levels, but on the other hand, also to a
relatively fast decrease in levels. Oral therapy might result in
lower but more steady plasma levels. It can be hypothesized
that PDA closure relies more on continuous prostaglandin
inhibition than on intermittent high paracetamol or NSAIDs
levels.
The relatively late start of paracetamol administration
might be the most important explanation for our disappointing
results compared to other studies. A second likely reason is the
low gestational ages in our study. Other studies with better
results [12, 19, 21, 29] included older infants with gestational
ages >28 weeks. PDAs in this age group are generally less
hemodynamically significant and tend to close spontaneously
and respond better to pharmacological treatment.
Ibuprofen therapy failure was previously found to be 17 %
in infants with gestational ages of 26–27weeks versus 62% in
23–25-week-old infants [6]. PDAs in more preterm born in-
fants are probably less responsive to cyclooxygenase inhibi-
tors due to higher expression of prostaglandin receptors [3].
Next to gestational age and postnatal age, clinical factors such
as the amount of fluids given, incidence of infections or sepsis,
type of respiratory support, and use of co-medication might be
influential factors for PDA closure success in extreme preterm
infants.
Third, selection bias may have occurred, in that, we includ-
ed patients in whom ibuprofen therapy had failed prior to
paracetamol treatment. As NSAIDs are more potent prosta-
glandin synthesis inhibitors than paracetamol [8], resulting in
lower peripheral PGE2 levels as is shown in orthodontic stud-
ies [25], the a priori probability of success of paracetamol in
this group of patients was already relatively low.
Pharmacokinetics and pharmacodynamics of paracetamol
for PDA closure have been hardly studied. Consequently, the
effective plasma level of paracetamol to achieve PDA closure
is unknown. The currently used dosages are already much
higher than recommended for analgesia, and might be unsafe.
Increasing the dose to improve closure rates is unadvisable. In
a study by Kessel et al., plasma levels of paracetamol
(15 mg/kg/6 h by nasogastric tube) did not exceed the recom-
mended plasma levels of 10–20 mg/l for pain and fever con-
trol [14]. Based on predictive modeling, plasma levels will
accumulate with the 15 mg/kg/6 h regimen, reaching peaks
of nearly 25mg/kg after four doses [1]. In very preterm infants
and murine studies, the effectiveness of paracetamol on PDA
closure was suggested to depend on dosing, duration of treat-
ment (>2 days course), and mode of administration [8].
Likewise, safety of paracetamol in very preterm infants
(gestational age <28 weeks) has been little studied. Allegaert
et al. showed no hemodynamic alterations during and follow-
ing an intravenous loading dose of paracetamol and afebrile
neonates maintained normothermia [2]. Paracetamol-induced
hepatotoxicity is the most important concern; this is caused by
the formation of a highly active metabolite N-acetyl-p-benzo-
quinone imine (NAPQ1) by the hepatic cytochrome P450-
dependent CYP2E1 enzyme system [28]. The formation of
Fig. 2 Change in ductus
arteriosus diameter after 3 to
maximum 7 days of intravenous
PCM treatment for the three
different groups (group A:
primary contraindication for
ibuprofen; group B: paracetamol
after early stop of ibuprofen; and
group C: paracetamol after
complete ibuprofen treatment)
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NAPQ1 is suggested to be low due to the immaturity of the
hepatic enzymes, although increased susceptibility to toxicity
from supratherapeutic paracetamol is described in infants and
younger children with fever [13]. CYP2E1 activity has not yet
been quantified in neonates and the correlation between para-
cetamol concentration and increased NAPQ1 production is
unknown.
Several limitations of this study should be addressed. First,
this was an observational single center study with relatively
few patients per group, without a matched control group to
rule out spontaneous PDA closure. Firm statements are there-
fore difficult to make. Second, the echocardiosonographer and
pediatric cardiologist were not blinded for the PDA treatment.
Third, only patients were included in our study after ibuprofen
failure or with a primary or secondary contraindication for
ibuprofen; this selection bias might have contributed to our
results.
Conclusions
In view of the findings from this study, we do not recommend
the use of intravenous paracetamol for hsPDA closure in
VLBW infants after ibuprofen failure. Still, as we did not rule
out effectiveness of paracetamol as early PDA treatment, it
might be recommended when started in the first week of life.
On the other hand, as long as data on long term safety are
lacking, high dosages of paracetamol should be used with
caution. Better designed PK/PD studies are needed to shed a
light on safety aspects and the optimal dose-concentration-
effect relationship. PK modeling of available data on PDA
treatment with paracetamol in different gestational age groups
can lead to different dosing recommendations per age group; a
trial with these dose recommendations of paracetamol for
PDA is also an option for future research.
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